/
OUR COMPANY NP Life Sciences Health Industry Group Inc. ( NP Life Sciences , NPLS , the Company , we , us or our ), formerly GJ Culture Group US, Inc, was formed as a Nevada corporation on December 20, 2018 for the purpose of providing educational and other related services based on classical Chinese studies and culture. We aim to serve as a cultural and educational meeting point between China …
$10.00
+$0.00 (+0.00%)
EOD Jul 17, 2026
The business is unprofitable at the operating level (-0.42% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 61.4% YoY with margins expanding 18.1pp.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$165K
▲ +61.4% YoY
Net Income (TTM)
-$3K
▲ +84.4% YoY
Op. Margin
-0.42%
▲ +18.1pp YoY
ROIC
-3.05%
▲ +48.8pp YoY
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow (TTM)
-$74K
▼ -178.4% YoY
Net Debt
-$71K
Net Cash Position
Cash & Equiv.
$71K
3Y CAGR: +122.2%
Continue Research
NP Life Sciences Health Industry Group (ACAT)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, NP Life Sciences Health Industry Group scores 48/100 on Intrinsiqq's quality scorecard, weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
NP Life Sciences Health Industry Group scores 48 out of 100 on Intrinsiqq's quality score, a weighted blend of 5 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a -0.4% operating margin and a -3.1% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh ACAT's valuation and scores 48/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.